Covovax Review: NTAGI’s Working Group To Review New Serum Vaccine

The COVID-19 working group of the National Technical Advisor (NTAGI) will review the new corona vaccine ‘Covovax’ developed by the Serum Institute of India (SII). This vaccine is designed for children and adults specifically. And the review meeting will be held on April 1.

The NTAGI set up for Immunization has a three-tier system to decide on a vaccine. This working group is of the first level review. A second-level Standing Technical Sub-Committee (STSC) will review and discuss the safety and effectiveness of the vaccine data after the working group looks at the safety and effectiveness of the vaccine data. Thereafter, STSC will give its decision to the third group to make the final decision.

Booster Dose Is Not For Everyone

In the meeting to be held on Friday, NTAGI will not discuss the booster or precautionary dose of COVID-19 for all the countrymen. Recently, the Drug Controller General of India (DCGI) has allowed the serum for emergency use of Covovax. This permission has been given to adults and children above the age of 12 years.

Meanwhile, Serum CEO Adar Poonawalla tweeted, “Novavax has been found to be more than 90% effective in global trials. Covovax, a brand of Serum Institute of India, has completed the study in India. Emergency access permission has been granted by DCGI for adults. Children over 12 years old will get it soon.”

183.79 D0ses Have Been Given In Country

So far 183.79 crores (1,83,79,06,022) have been given doses under the ongoing corona vaccination in the country. More than 1.50 crore (1,50,55,291) vaccine doses have been administered so far under the recently launched Vaccine Campaign for children in the age group of 12 to 14.